



Hemodynamic Monitoring

Results Presentation Year ended 31 January 2020

21st April 2020

Matt Sassone CEO Tim Hall CFO

www.lidco.com

Disclaimer



The information contained in this presentation document (the "presentation", which term includes any information provided verbally in connection with this presentation document) does not constitute an offer or solicitation to hold, sell or invest in any security and should not be considered as investment advice or as a sufficient basis on which to make investment decisions. This presentation is being provided to you for information purposes only.

The Presentation Materials includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will", or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include matters that are not historical facts and include statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the anticipated future performance of the Company. Any such forward-looking statements in the Presentation Materials reflect the Company's current expectations and projections about future events but, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Save as required by law or regulation or the rules of any securities exchange, the Company undertakes no obligation to release the results of any revisions to any forward-looking statements in this Presentation that may occur due to any change in its expectations or to reflect events or circumstances after the date of the Presentation Materials. In particular, no representation or warranty is given by the Company as to the achievement of, and no reliance should be placed on, any projections, targets, estimates or forecasts and nothing in the Presentation Materials is or should be relied on as a promise or representation as to any future event.





Key FY20 Highlights

- LiDCO product revenue up 19% to £7.4m
- Differentiated business model, HUP, up 101% to £1.9m
- Adjusted EBITDA* improved by £1.2m to break-even

* adjusted for share-based payments

Post Year End

- Increased demand due to CV-19, 195 monitors sold to date.
 Compared with 219 monitors in the whole of FY20
- Board expects FY21 Q1 sales will significantly exceed total sales of £3.5m achieved in H1 FY20



Use of technology for CV-19



LiDCO's monitoring enables doctors to titrate fluid and drugs to patients in order to manage their hemodynamic stability. Patients with CV-19 often develop severe respiratory illness resulting in admission to intensive care.



- Fluid balance is critical in order to manage patients' lungs
- Recommendations include checking preload ('fluid') responsiveness to optimise cardiac performance and end organ perfusion, yet typical methods may be unsuitable by current COVID-19 ventilation treatment recommendations



- LiDCO offers several new, evidence-based protocols to guide the physician on whether their patient is fluid responsive
- They include: Guided Fluid Challenge, Guided Passive Leg Raise, End Expiratory Occlusion Test, Lung Recruitment Maneuver and Tidal Volume Challenge

Intensive care management of COVID-19: challenges and recommendations. Lancet Respir Med 2020. 10.1016/S2213-2600(20)30165-X



Impact of CV-19



TAILWINDS

- Significant short term increased demand
- New customers gained as a result
- Hospital capital purchases defends against competition
- Enlarged installed base has potential to drive increased recurring revenues
- Large inventory holding buffered supply chain delays


HEADWINDS

- Cancelled elective surgery impact minimised by HUP business model
- Delayed purchasing decisions will impact H2 growth, especially in US
- Hospital capital purchases from competition reduces new prospects
- Uncertainty regarding future healthcare budgets
- Single source regulatory approved supply chain


PEOPLE – Production staff transitioned to two shifts in order to ensure continuity of supply. Commercial teams unable to visit customers but all other staff able to work from home.


Summary of FY20 Financials






Gross Profit (£m)







* Before Share-based Payments

[†] Restated for IFRS16, allocation of certain expenses to COGS

DEBT FREE CASH 31/1/20 £1.36m

0

info@lidco.com

www.lidco.com

Income Statement

Income Statement				
	Year ended 31 January 2020 £'000	Year ended 31 January 2019 £'000	1	Tot Co: ove
Revenue Cost of sales Gross profit	7,547 (2,627) 4,920	7,324 (3,026) 4,298	1	Gro to 6
Sales and marketing Development & regulatory Administration Overhead costs	(3,419) (783) (1,824) (6,026)	(3,787) (798) (1,708) (6,293)	1	
Adjusted operating loss Share-based payments	(1,106) (96)	(1,995) (143)		Fin IFR
Operating loss Finance income Finance expense Loss before tax	(1,202) 1 (13) (1,214)	(2,138)	•	Los (FY

185

(56)

(1,029)

196

(1,941)

(1,306)



- tal revenues increased 3% to £7.55m
- ost of sales includes labour & direct erheads of £514k (FY19: £537k)
- oss margin on LiDCO products increased 66.8% (FY19: 65.8%)
- verhead costs reduced by 4.2% due to:
 - Reduction of 6 in average headcount to 44
 - Strict control of costs

O,

- Partly offset by higher bonuses/commissions
- nance expense arises from the adoption of **RS16**
- ss after tax decreased 47% to £1.03m Y19: £1.94m)
- EBITDA loss decreased by £1.25m to £56k with £216k of decrease coming from adoption of IFRS 16
- EBITDA in H2 £205k (H2 FY19: loss £422k)

info@lidco.com

Income tax

EBITDA

Loss after tax

Balance Sheet

	31 January 2020 £'000	31 January 2019 £'000
Property, plant & equip't	867	949
Right-of-use assets	224	-
Intangible assets	2,342	2,083
Non-current assets	3,433	3,032
Current assets		
Inventory	1,545	1,880
Trade & other receivables	1,986	1,928
Tax receivable	183	188
Cash	1,360	1,717
Total current assets	5,074	5,713
Current liabilities		
Trade & other payables	(1,556)	(1,374)
Deferred income	(1,230)	(837)
Total current liabilities	(2,786)	(2,211)
Net current assets	2,288	3,502
Non-current liabilities		
Lease liabilities	(120)	-
Net assets	5,601	6,534



- Right-of-use assets recognised on adoption of IFRS 16, relate to facility lease and cars
- £209k of increase in intangibles relates to a new ERP system
- Part of inventory reduction due to an increase in stock provisions of £183k
- Cash increased by £172k in H2
- Increase in payables driven by lease liabilities (+£116k) and accruals (+£108k)
- Increase in deferred income reflects prepayments from growing HUP customer base
- Long-term lease liability relatively low due to short remaining term on Orsman Rd lease
- Company remains debt free

O,

Cash Flow & Working Capital


	Year ended 31 January	Year ended 31 January
	2020 £000	2019 £000
Loss before tax	(1,214)	(2,137)
Net finance expense/(income)	12	(1)
Depreciation & amortisation	1,146	832
Share-based payments	96	143
Adjusted EBITDA	40	(1,163)
Deferred income	393	169
Working capital	320	350
Taxation	192	135
Cash flow from operating activities	945	(509)
Cash used in investing activities	(1,099)	(1,001)
Net cash flow before financing	(154)	(1,510)
Net cash flow - financing activities	(203)	-
Net change in cash	(357)	(1,510)
Opening cash	1,717	3,227
Closing cash	1,360	1,717

- Depreciation & amortisation increased by £314k with £223k due to adoption of IFRS 16, and £78k from increases in the number of medical monitors
- Positive Adjusted EBITDA of £40k,a £1.20m increase on FY19
- Cash flow used in investing activities consists of £306k PPE (monitors £261k), £794k intangibles (product development £521k) less £1k of finance income
- Cash outflow from financing activities represents principal elements of lease payments and associated interest
- Net cash outflow decreased by £1.15m to £357k. Positive £172k in H2.


O,

FY20 LiDCO Product Revenues






% growth vs FY19



By revenue type (£m)




- Over 50% of revenues generated outside UK
- 75% recurring revenues
- License revenues represent 30% of revenues
- US Driven by HUP software license success
- UK Remain market leader
- EU Rebuilding business with new distributors
- ROW Relaunch in China driving growth



HUP Performance





Since launch July 2017:

- 286 monitors signed on the Software as a Service "SaaS" model
- US: 156 monitors spread across 15 hospital accounts
- 26% of UK business converted to HUP
- Total annualised contract value (ACV) £2.3m
- £7.6m total value of HUP contracts signed
- 98% Retention rate

HUP REVENUES UP 101% to £1.9m (FY19: £0.9m)

രി

Product Development




NEW License Modes



- The Per Patient license allows for the sale of a block of uses for either arterial and/or non-invasive use, without the need for a disposable.
- The uses can be topped up over time as they run out.

NEW Non-Invasive Features



- Reducing the time to start monitoring to less than a minute
- Automatic incorrect sensor size recognition to reduce mistakes
- Improved signal optimisation, for more reliable short- and long-term blood pressure tracking

Office Relocation



Changes agreed to Orsman Rd lease

- Compensation to be paid upon LiDCO vacating the premises which increases with each month before 23 June 2021 that vacation occurs
- LiDCO may terminate the lease from 23 June 2020 on one month's notice
- Rent reduced by 12.5%
- Total compensation expected to cover the fit-out costs of new premises

New premises

- Production and distribution moving to a new facility in the northern outskirts of London
- Ten-year lease signed and fit-out ongoing
- Clean room activities are being outsourced to a contract manufacturer

- 3-year lease signed for office space in central London effective from 1 May
- Semi-serviced office with shared amenities
- Plans to move by 23 June may be disrupted by COVID-19







- Short-term spike in demand as a result of CV-19
- Travel and marketing costs substantially reduced due to restrictions
- Board expects that the Group will benefit from strong cash inflows in the first half of the current financial year
- Delayed purchasing decisions as buyers focused on the short-term needs associated with CV-19
- Board remains confident that LiDCO will be well placed when markets return to normal

Summary



- Strong LiDCO product growth in FY20
- FY21 has benefited from CV-19 demand
- Company is well positioned to take further market share through appealing 'Software As A Service' model when markets return to normal
- Fundamentals of business very attractive
- Balance sheet supports growth strategy



Appendix

info@lidco.com



Ø

www.lidco.com

LiDCO investing headlines





Large and growing global market



Geographical expansion from UK 60% market share base*



Differentiated business model enabling share expansion




Recent sector M&A valuations 4-7 times revenue

* internal management estimate



LiDCO Timeline





Proven to improve patient outcomes Lidco


Independent studies using **LiDCO** technology have been shown to **improve outcomes** in:

High risk elective surgery Emergency surgery **Intensive Care**

Colorectal, Vascular, Hip replacement, Liver Resection, Oesophagectomy, Bariatric, Cardiac, Abdominal, Caesarean, Emergency Laparotomy

High risk surgical patients in ICU, Septic shock patients in ICU


Reducing patient deaths



Reducing length of stay

Using LiDCO as part of an Enhanced Recovery program in **Colorectal** surgery has been shown to statistically reduce length of stay (LOS)³






Market Overview



Enhanced Recovery to Accelerate Segment Growth



1. Third party research and internal estimates 2. Includes pulmonary artery catheters and invasive pressure monitoring products, excludes capital 3. Includes minimally invasive and non-invasive advanced hemodynamic monitoring products, excludes capital

info@lidco.com




Competitive Landscape



Competitive Landscape Changing Due To Recent Acquisitions

Advanced Recovery Hemodynamics Market Share*



* Source: internal estimates based on published data

info@lidco.com



Recent sector acquisitions



cheetah medical	2019	Baxter Healthcare	Acquired for \$190 million with additional \$40 million based on clinical & commercial milestones	Revenues \$25m* LBITDA - \$5m*
CASMED. FOR WHAT'S VITAL	2019	Edwards Lifesciences	Acquired for \$100m	Revenues \$21m LBITDA - \$6.4m
PULSION Medical Systems	2014	Getinge AB	Acquired for €139m	Revenues €34m EBITDA €12m
bmeye .	2012	Edwards Lifesciences	Acquired for €28m	Revenues €4m* EBITDA -€1m*
				 * Private companies. Management estimates

LIDCO MARKET CAP £22M (2.9 X FY20 REVENUE)*

* 20/04/20 Closing share price.t

info@lidco.com





0

www.lidco.com

Differentiated business offering







В

Competitor set-up

Difference between two methods:


- No need to change from standard pressure transducer
- No need for an expensive per patient disposable
- No need to increase infection risk by 'breaking the line'
- LiDCO is pressure transducer agnostic



LiDCO – HUP strategy



OFFERING



രി

STRATEGY

HUP Custo	omer Experi	ence	Lidco
Large NHS Teaching H	lospital	Leading US	Academic Hospital
Before 4065 Patients	Circa £0.3m	2900 Patients	Circa \$1.0m \$\$\$\$\$\$\$\$ Costs
After first year of HUP			
5838 Patients	ZERO increase	5315 Patients	over \$0.5m \$\$\$\$ Savings
Direct savings Potential Indirect savings*	<f0.1m p.a.<br="">f1mtof1.7m p.a.</f0.1m>	Total Direct savings Potential Indirect savings*	>\$1.2m _{p.a.} \$1.8mto\$3.1m _{p.a.}

* Calculated using potential cost-savings per patient when using goal-directed fluid therapy as identified in the following clinical paper - Michard et al. Perioperative Medicine (2015) 4:11 DOI 10.1186/s13741-015-0021-0

info@lidco.com



Board





Peter Grant

Non-Executive Chairman

- Former Chief Executive Officer of Skyepharma PLC
- Former Chief Financial Officer at WorldPay plc & Group Chief Executive at Molins PLC



Matt Sassone

Chief Executive Officer

- 20+ years medical device experience
- Former Chief Marketing Officer of Maquet
- Former Regional President for Smiths Medical



Tim Hall

Chief Financial Officer

- Chartered Accountant with 30 years' experience
- Former Chief
 Financial Officer of
 Oxford Gene
 Technology IP Ltd &
 Lombard Medical
 Technologies PLC



Phil Cooper

Non-Executive Director

- 30 years medical device experience
- Former president of the wound care division Mölnlycke Health Care

6



Jim Wetrich

Non-Executive Director

- 35 years of experience in the US healthcare industry
- Former Executive at Abbott Laboratories, Mölnlycke Health Care, Premier Inc, and Providence Health & Services.

www.lidco.com



Clinical References



1: Evaluation of the utility of the Vigileo FloTracTM, LiDCOTM, USCOM and CardioQTM to detect hypovolaemia in conscious volunteers: a proof of concept study. Reference: Anaesthesia 2015, 70, 142–149

2: Hata J, Stotts C, Shelsky C, Bayman E, Frazier A, Wang J, Nickel E (2011) Reduced mortality with noninvasive hemodynamic monitoring of shock. J Crit Care vol 26 (2):224. E1-8

3: Miller T, Thacker J, White W, Mantyh C, Migaly J, Jin J, Roche A, Eisenstein E, Edwards R, Anstrom K, Moon R, Gan TJ (2014) Anesth Analg 2014;118:1052–61

4: Eduardo A. Osawa; Andrew Rhodes; Giovanni Landoni; Filomena R. B. G. Galas; Julia T. Fukushima, et al. Effect of Perioperative Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes Following Cardiac Surgery: A Randomized Clinical Trial and Systematic Review General High Risk Surgery. Crit Care Med. 2016 Apr;44(4):724-33. doi: 10.1097/CCM.00000000001479

5: Fitzgerald T, Mosquera C, Koutlas N, Vohra N, Lee K, Zervos E. Enhanced recovery after surgery in a single high-volume surgical oncology unit: Details matter. Presented at the 11th Annual Academic Surgical Congress (ASC), Jacksonville, Florida, Feb 2016

6: American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on perioperative fluid management within an enhanced recovery pathway for colorectal surgery. Thiele et al. Perioperative Medicine (2016) 5:24 DOI 10.1186/s13741-016-0049-9

7: Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Cecconi et al. Intensive Care Med DOI 10.1007/s00134-014-3525-z

8: NICE Medical technologies guidance [MTG3]. https://www.nice.org.uk/guidance/mtg3/resources

